Clinical Evidence of Antifungal Activity Supports Antimicrobial Breadth of Nitric Oxide Platform

Novan, Inc. ('the Company' or 'Novan') (NASDAQ:NOVN) today announced positive topline results from the Company's Phase 2 clinical trial with SB208, a topical, silicone based-gel under development for the treatment of infections caused by dermatophytes such as Trichophyton rubrum, or T. rubrum. Novan is developing SB208 as a broad-spectrum antifungal gel for the treatment of superficial cutaneous fungal infections of the skin and nails, including tinea pedis and onychomycosis. Novan's SB208 Gel, at both the 4% and 16% concentrations, demonstrated a statistically significant effect (p<0.05) compared to vehicle in a clinical trial in patients with tinea pedis, or athlete's foot. Clinical activity against dermatophytes was measured by incidence of a negative fungal culture after two weeks of treatment.

Read the full press releaseCompany website

Malin Corporation plc published this content on 12 April 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 20 April 2017 09:12:08 UTC.

Original documenthttp://www.malinplc.com/investee-company-news/novan-reports-positive-topline-results-with-sb208-in-phase-2-trial/

Public permalinkhttp://www.publicnow.com/view/B1BAF95D653750808405DCF99147404DE3E39EF3